Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 19/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 16/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019771 | 0.85 | ALDH1A1 (0.48) | NPC1PKMRAB9AKMT2A | |
| SCHEMBL14887484 | 0.85 | CRACR2A (0.45) | RAB9ACYP1A2 | |
| SCHEMBL16017197 | 0.84 | ALDH1A1 (0.58) | MEN1RAB9AKMT2ACYP1A2 | |
| SCHEMBL16017209 | 0.83 | RAB9A (0.47) | NPC1RAB9ACYP1A2 | |
| SCHEMBL16017200 | 0.82 | CRACR2A (0.44) | RAB9ACYP1A2 | |
| SCHEMBL14887705 | 0.82 | CRACR2A (0.58) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL16017189 | 0.82 | STIM1 (0.51) | RAB9ACYP1A2 | |
| SCHEMBL16019773 | 0.82 | GRM1 (0.48) | GRM1GRM4NPC1RAB9A | |
| SCHEMBL16017182 | 0.82 | BACE1 (0.44) | RAB9AKMT2A | |
| SCHEMBL14887330 | 0.82 | CRACR2A (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | GRM1 1425/4885GRM4 1253/4885MEN1 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.